Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (PODD) delivers innovative diabetes management solutions through its flagship Omnipod® insulin pump system. This page aggregates official news and developments about the company's medical device innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates including quarterly earnings reports, product launch announcements, regulatory milestones, and partnership agreements. All content is sourced directly from verified corporate communications to ensure accuracy.
Key coverage areas include FDA clearances for new devices, clinical study results, international market entries, and technology partnerships enhancing insulin delivery systems. The resource is particularly valuable for tracking advancements in tubeless pump technology and automated insulin dosing integrations.
Bookmark this page for streamlined access to Insulet's latest developments in diabetes care innovation. Check regularly for updates that may impact long-term growth strategies or patient care standards.
Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced the launch of its Omnipod 5 Automated Insulin Delivery System in France, now available for people aged two and older and compatible with the Dexcom G6 CGM. The French National Authority for Health has granted reimbursement status for the system.
In the U.S., Insulet has commenced the full commercial launch of Omnipod 5 with Dexcom G7 integration, offering users a new Pod compatible with both Dexcom G6 and G7 sensors. Additionally, the Omnipod 5 App for iPhone has begun a market release, initially integrating with Dexcom G6, with future updates to include Dexcom G7 compatibility.
These milestones reflect Insulet's commitment to expanding access to its innovative diabetes management technology globally.
Insulet (NASDAQ: PODD) announced that its management will present at the Jefferies Global Healthcare Conference in New York City on June 6, 2024, at 9:00 a.m. ET. The presentation will be accessible via a live audio webcast on the company's investor relations site, with a replay available post-event.
Insulet is renowned for its Omnipod® product platform, a tubeless insulin pump technology aimed at simplifying life for people with diabetes. The Omnipod Insulin Management System offers up to three days of non-stop insulin delivery without needle handling. Their latest innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor and can be controlled via smartphone or the Omnipod 5 Controller. Insulet is also exploring the use of its Omnipod technology for non-insulin subcutaneous drug delivery.
Insulet (NASDAQ: PODD) reported a 23% year-over-year revenue increase in the first quarter of 2024, with total revenue reaching $441.7 million. The Company exceeded its guidance range due to revenue outperformance across all product lines. Gross margin increased to 69.5%, operating income rose to $56.9 million, and net income reached $51.5 million. Insulet also achieved strong new customer starts, expanded market share globally, and launched new products like Omnipod 5 integrated with Dexcom's G7 sensor. The company is raising its full-year revenue and operating margin guidance for 2024.
Insulet (NASDAQ: PODD) released its 2023 Sustainability Report highlighting achievements in environmental, social, and governance areas. The report focuses on product accessibility, responsible growth, affordability, resilient operations, and sustainable product innovation. Insulet reached 425,000 active global customers, expanded financial assistance programs, generated renewable energy, reduced waste, and enhanced product sustainability. The company conducted a comprehensive double materiality assessment to prioritize initiatives and ensure operational resilience.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
